Smoker and non-smoker lung adenocarcinoma is characterized by distinct tumor immune microenvironments

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D, et al. Lung cancer occurrence in never-smokers: an analysis of 13 Cohorts and 22 cancer registry studies. PLoS Med. 2008. doi:10.1371/journal.pmed.0050185.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci. 2004;101:13306–13311. doi:10.1073/pnas.0405220101.
   PubMed Web of Science ®Google Scholar
• Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer. 2001;92:1525–1530.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 1992;52:734–736.
   Google Scholar
• Husgafvel-Pursiainen K, Boffetta P, Kannio A, Nyberg F, Pershagen G, Mukeria A, et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res. 2000;60:2906–2911.
   PubMed Web of Science ®Google Scholar
• Goncalves RB, Coletta RD, Silverio KG, Benevides L, Casati MZ, Da Silva JS, et al. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm Res. 2011;60:409–424. doi:10.1007/s00011-011-0308-7.
   PubMed Web of Science ®Google Scholar
• Quail D, Joyce J. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437. doi:10.1038/nm.3394.
   PubMed Web of Science ®Google Scholar
• Mountzios G, Fouret P, Soria JC. Mechanisms of disease: signal transduction in lung carcinogenesis – a comparison of smokers and never-smokers. Nat Clin Pract Oncol. 2008;5:610–618. doi:10.1038/ncponc1181.
   PubMedGoogle Scholar
• Wong MP, Fung LF, Wang E, Chow WS, Chiu SW, Lam WK, et al. Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. Cancer. 2003;97:1263–1270. doi:10.1002/cncr.11183.
   PubMed Web of Science ®Google Scholar
• Zeka A, Mannetje A, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, et al. Lung cancer and occupation in nonsmokers: a multicenter case-control study in Europe. Epidemiology. 2006;17:615–623. doi:10.1097/01.ede.0000239582.92495.b5.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–457. doi:10.1038/nmeth.3337.
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220. doi:10.1186/s13059-017-1349-1.
   PubMed Web of Science ®Google Scholar
• Toyoshima E, Ohsaki Y, Nishigaki Y, Fujimoto Y, Kohgo Y, Kikuchi K. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor. Lung Cancer. 2001;31:193–202.
   PubMed Web of Science ®Google Scholar
• Bienenstock J. The lung as an immunologic organ. Annu Rev Med. 1984;35:49–62. doi:10.1146/annurev.me.35.020184.000405.
   PubMed Web of Science ®Google Scholar
• Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33:119–126. doi:10.1016/j.it.2011.12.001.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–896. doi:10.1038/ni.1937.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer. 2008;113:1387–1395. doi:10.1002/cncr.23712.
   PubMed Web of Science ®Google Scholar
• Trojan A, Urosevic M, Dummer R, Giger R, Weder W, Stahel RA. Immune activation status of CD8+T cells infiltrating non-small cell lung cancer. Lung Cancer. 2004;44:143–147. doi:10.1016/j.lungcan.2003.11.004.
   PubMed Web of Science ®Google Scholar
• Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003;94:1003–1009.
   PubMed Web of Science ®Google Scholar
• Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8(+) T cells and CD4(+) T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94:275–280. doi:10.1038/sj.bjc.6602934.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, Zhao HQ, Li TW, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17. doi:10.1186/s13059-016-1028-7.
   Web of Science ®Google Scholar
• Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clinical Oncology. 2005;23:8959–8967. doi:10.1200/JCO.2005.01.4910.
   PubMed Web of Science ®Google Scholar
• Imada A, Shijubo N, Kojima H, Abe S. Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J. 2000;15:1087–1093.
   PubMed Web of Science ®Google Scholar
• Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol. 2006;117:1214–1225. quiz 26. doi:10.1016/j.jaci.2006.04.015.
   PubMed Web of Science ®Google Scholar
• Rigoni A, Colombo MP, Pucillo C. The role of mast cells in molding the tumor microenvironment. Cancer Microenviron. 2015;8:167–176. doi:10.1007/s12307-014-0152-8.
   PubMed Web of Science ®Google Scholar
• Small-Howard A, Turner H. Exposure to tobacco-derived materials induces overproduction of secreted proteinases in mast cells. Toxicol Appl Pharmacol. 2005;204:152–163. doi:10.1016/j.taap.2004.09.003.
   PubMed Web of Science ®Google Scholar
• Mortaz E, Redegeld FA, Sarir H, Karimi K, Raats D, Nijkamp FP, et al. Cigarette smoke stimulates the production of chemokines in mast cells. J Leukoc Biol. 2008;83:575–580. doi:10.1189/jlb.0907625.
   PubMed Web of Science ®Google Scholar
• Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8:3803–3812.
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Caramori G, Gnemmi I, Contoli M, Bristot L, Capelli A, et al. Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD. Thorax. 2009;64:968–975. doi:10.1136/thx.2009.113647.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014;2014:1–12. doi:10.1155/2014/292376.
   Web of Science ®Google Scholar
• Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F, et al. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J. 2003;373:547–558. doi:10.1042/BJ20030207.
   PubMed Web of Science ®Google Scholar
• Kuner R, Muley T, Meister M, Ruschhaupt M, Buness A, Xu EC, et al. Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. Lung Cancer-J Iaslc. 2009;63:32–38. doi:10.1016/j.lungcan.2008.03.033.
   PubMed Web of Science ®Google Scholar
• Hou J, Aerts J, Den Hamer B, Van Ijcken W, Den Bakker M, Riegman P, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PloS One. 2010;5:e10312. doi:10.1371/journal.pone.0010312.
   PubMed Web of Science ®Google Scholar
• Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013;5:186ra66. doi:10.1126/scitranslmed.3005723.
   PubMed Web of Science ®Google Scholar
• Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012;72:100–111. doi:10.1158/0008-5472.CAN-11-1403.
   PubMed Web of Science ®Google Scholar
• Yamauchi M, Yamaguchi R, Nakata A, Kohno T, Nagasaki M, Shimamura T, et al. Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma. PloS One. 2012;7:e43923. doi:10.1371/journal.pone.0043923.
   PubMed Web of Science ®Google Scholar
• Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013;19:194–204. doi:10.1158/1078-0432.CCR-12-1139.
   PubMed Web of Science ®Google Scholar
• Der SD, Sykes J, Pintilie M, Zhu CQ, Strumpf D, Liu N, et al. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients. J Thoracic Oncol. 2014;9:59–64. doi:10.1097/JTO.0000000000000042.
   PubMed Web of Science ®Google Scholar
• Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PloS One. 2008;3:e1651. doi:10.1371/journal.pone.0001651.
   PubMed Web of Science ®Google Scholar
• Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clinical Oncology. 2010;28:4417–4424. doi:10.1200/JCO.2009.26.4325.
   PubMed Web of Science ®Google Scholar
• Girard LMJ, Gerald WL, Saintigny P, Zhang L. MSKCC—a primary lung cancer specimens. Gene Express Omnibus GSE31547; 2011.
   Google Scholar
• Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008;14:822–827. doi:10.1038/nm.1790.
   PubMed Web of Science ®Google Scholar
• Su LJ, Chang CW, Wu YC, Chen KC, Lin CJ, Liang SC, et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics. 2007;8:140. doi:10.1186/1471-2164-8-109.
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity (vol 483, pg 603, 2012). Nature. 2012;492:290. doi:10.1038/nature11798.
   Web of Science ®Google Scholar
• Stransky N, Ghandi M, Kryukov GV, Garraway LA, Lehar J, Liu M, et al. Pharmacogenomic agreement between two cancer cell line data sets. Nature. 2015;528:84.
   PubMed Web of Science ®Google Scholar